Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Private equity player Celtic bankrolls new Swiss antibody-drug conjugate company

This article was originally published in Scrip

Executive Summary

Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, is leveraging the power of a technology platform owned by portfolio company Spirogen to create a new company focused on antibody drug conjugate (ADC) products. Alongside other Spirogen shareholders, Celtic Therapeutics is earmarking up to $50million for Lausanne, Switzerland-based ADC Therapeutics to develop a pipeline of 10 proprietary antibody drug conjugate oncology development programmes, targeting multiple major cancers, including prostate, renal, breast, lung and blood cancers.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts